Loading...

Getinge

DB:GTN
Snowflake Description

Mediocre balance sheet with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
GTN
DB
SEK38B
Market Cap
  1. Home
  2. DE
  3. Healthcare
Company description

Getinge AB provides products and solutions for operating rooms, intensive-care units, sterilization departments, and life science companies and institutions. The last earnings update was 5 days ago. More info.


Add to Portfolio Compare Print
GTN Share Price and Events
7 Day Returns
-9.7%
DB:GTN
2.2%
DE Medical Equipment
-0.7%
DE Market
1 Year Returns
46.8%
DB:GTN
6.2%
DE Medical Equipment
-7.6%
DE Market
GTN Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Getinge (GTN) -9.7% -7.9% 13.7% 46.8% -28.9% -30.8%
DE Medical Equipment 2.2% -1.6% 3.2% 6.2% 112.8% 263.8%
DE Market -0.7% -0.8% -3.8% -7.6% 8.2% 11.1%
1 Year Return vs Industry and Market
  • GTN outperformed the Medical Equipment industry which returned 6.2% over the past year.
  • GTN outperformed the Market in Germany which returned -7.6% over the past year.
Price Volatility
GTN
Industry
5yr Volatility vs Market

Value

 Is Getinge undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Getinge to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Getinge.

DB:GTN Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 10 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 6.5%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:GTN
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Medical Equipment Unlevered Beta Simply Wall St/ S&P Global 0.87
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.87 (1 + (1- 22%) (30.9%))
1.053
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.05
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.053 * 5.96%)
6.5%

Discounted Cash Flow Calculation for DB:GTN using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Getinge is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:GTN DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (SEK, Millions) Source Present Value
Discounted (@ 6.5%)
2020 1,828.83 Analyst x6 1,717.15
2021 2,459.25 Analyst x4 2,168.05
2022 2,890.00 Analyst x1 2,392.20
2023 3,322.00 Analyst x1 2,581.86
2024 3,647.92 Est @ 9.81% 2,662.02
2025 3,900.94 Est @ 6.94% 2,672.81
2026 4,093.00 Est @ 4.92% 2,633.15
2027 4,236.87 Est @ 3.51% 2,559.24
2028 4,344.01 Est @ 2.53% 2,463.72
2029 4,423.88 Est @ 1.84% 2,355.79
Present value of next 10 years cash flows SEK24,205.99
DB:GTN DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= SEK4,423.88 × (1 + 0.23%) ÷ (6.5% – 0.23%)
SEK70,647.45
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= SEK70,647.45 ÷ (1 + 6.5%)10
SEK37,620.94
DB:GTN Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= SEK24,205.99 + SEK37,620.94
SEK61,826.93
Equity Value per Share
(SEK)
= Total value / Shares Outstanding
= SEK61,826.93 / 272.37
SEK227
DB:GTN Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:GTN represents 0.09248x of OM:GETI B
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.09248x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (SEK) x Listing Adjustment Factor
= SEK 227.00 x 0.09248
€20.99
Value per share (EUR) From above. €20.99
Current discount Discount to share price of €12.85
= -1 x (€12.85 - €20.99) / €20.99
38.8%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Getinge is available for.
Intrinsic value
39%
Share price is €12.85 vs Future cash flow value of €20.99
Current Discount Checks
For Getinge to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Getinge's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Getinge's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Getinge's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Getinge's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:GTN PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in SEK SEK-2.32
OM:GETI B Share Price ** OM (2019-07-22) in SEK SEK138.95
Germany Medical Equipment Industry PE Ratio Median Figure of 10 Publicly-Listed Medical Equipment Companies 31.82x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 19.75x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Getinge.

DB:GTN PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OM:GETI B Share Price ÷ EPS (both in SEK)

= 138.95 ÷ -2.32

-59.88x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Getinge is loss making, we can't compare its value to the DE Medical Equipment industry average.
  • Getinge is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Getinge's expected growth come at a high price?
Raw Data
DB:GTN PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -59.88x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 10 Analysts
25.9%per year
Germany Medical Equipment Industry PEG Ratio Median Figure of 7 Publicly-Listed Medical Equipment Companies 2.49x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.44x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Getinge, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Getinge's assets?
Raw Data
DB:GTN PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in SEK SEK71.72
OM:GETI B Share Price * OM (2019-07-22) in SEK SEK138.95
Germany Medical Equipment Industry PB Ratio Median Figure of 13 Publicly-Listed Medical Equipment Companies 4.12x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.71x
DB:GTN PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OM:GETI B Share Price ÷ Book Value per Share (both in SEK)

= 138.95 ÷ 71.72

1.94x

* Primary Listing of Getinge.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Getinge is good value based on assets compared to the DE Medical Equipment industry average.
X
Value checks
We assess Getinge's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Getinge has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Getinge expected to perform in the next 1 to 3 years based on estimates from 10 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
25.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Getinge expected to grow at an attractive rate?
  • Getinge's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Getinge's earnings growth is expected to exceed the Germany market average.
  • Getinge's revenue growth is positive but not above the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:GTN Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:GTN Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 10 Analysts 25.9%
DB:GTN Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 10 Analysts 3.8%
Germany Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 12.7%
Germany Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 6.3%
Germany Market Earnings Growth Rate Market Cap Weighted Average 12.5%
Germany Market Revenue Growth Rate Market Cap Weighted Average 5.2%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:GTN Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 weeks ago) See Below
Future Estimates Average of up to 10 Analyst Estimates (S&P Global) See Below
All numbers in SEK Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:GTN Future Estimates Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 30,635 4,854 2,884 1
2022-12-31 29,577 4,369 2,446 1
2021-12-31 28,172 3,636 2,060 7
2020-12-31 26,962 2,868 1,723 10
2019-12-31 26,296 3,003 1,324 7
DB:GTN Past Financials Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income *
2019-06-30 25,398 3,082 -632
2019-03-31 24,852 2,592 -654
2018-12-31 24,172 2,503 -967
2018-09-30 23,653 2,899 -727
2018-06-30 22,914 2,371 847
2018-03-31 22,552 2,193 676
2017-12-31 22,495 2,763 1,096
2017-09-30 17,061 3,466 596
2017-06-30 19,046 3,599 390
2017-03-31 20,604 3,839 701
2016-12-31 22,170 3,671 698
2016-09-30 29,650 3,372 1,203

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Getinge's earnings are expected to grow significantly at over 20% yearly.
  • Getinge's revenue is expected to grow by 3.8% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:GTN Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 weeks ago) See Below
Future Estimates Average of up to 10 Analyst Estimates (S&P Global) See Below

All data from Getinge Company Filings, last reported 3 weeks ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:GTN Future Estimates Data
Date (Data in SEK Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 10.59 10.59 10.59 1.00
2022-12-31 8.98 8.98 8.98 1.00
2021-12-31 7.44 8.56 6.16 6.00
2020-12-31 6.32 7.29 5.45 7.00
2019-12-31 4.83 5.83 4.21 6.00
DB:GTN Past Financials Data
Date (Data in SEK Millions) EPS *
2019-06-30 -2.32
2019-03-31 -2.40
2018-12-31 -3.55
2018-09-30 -2.67
2018-06-30 3.16
2018-03-31 2.61
2017-12-31 4.37
2017-09-30 2.43
2017-06-30 1.61
2017-03-31 2.90
2016-12-31 2.89
2016-09-30 5.05

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Getinge is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Getinge's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Getinge has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Getinge performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Getinge's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Getinge does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Getinge's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Getinge's 1-year growth to the DE Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
Getinge's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Getinge Company Filings, last reported 3 weeks ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:GTN Past Revenue, Cash Flow and Net Income Data
Date (Data in SEK Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 25,398.00 -632.00 8,628.00 724.00
2019-03-31 24,852.00 -654.00 8,455.00 718.00
2018-12-31 24,172.00 -967.00 8,292.00 691.00
2018-09-30 23,653.00 -727.00 8,047.00 676.00
2018-06-30 22,914.00 847.00 7,867.00 670.00
2018-03-31 22,552.00 676.00 7,747.00 642.00
2017-12-31 22,495.00 1,096.00 7,740.00 594.00
2017-09-30 17,061.00 596.00 5,858.00 504.00
2017-06-30 19,046.00 390.00 6,360.00 496.00
2017-03-31 20,604.00 701.00 6,783.00 500.00
2016-12-31 22,170.00 698.00 7,201.00 538.00
2016-09-30 29,650.00 1,203.00 9,512.00 628.00
2016-06-30 29,646.00 1,462.00 9,561.00 624.00
2016-03-31 29,900.00 1,410.00 9,777.00 607.00
2015-12-31 30,235.00 1,390.00 9,905.00 598.00
2015-09-30 29,303.00 1,429.00 9,722.00 574.00
2015-06-30 28,603.00 1,622.00 9,471.00 574.00
2015-03-31 27,749.00 1,850.00 9,069.00 591.00
2014-12-31 26,669.00 1,433.00 8,596.00 597.00
2014-09-30 25,843.00 1,672.00 8,403.00 620.00
2014-06-30 25,468.00 1,718.00 8,180.00 620.00
2014-03-31 25,157.00 1,776.00 8,040.00 612.00
2013-12-31 25,287.00 2,285.00 7,962.00 619.00
2013-09-30 25,345.00 2,105.00 8,061.00 602.00
2013-06-30 25,070.00 2,210.00 8,017.00 594.00
2013-03-31 24,666.00 2,283.00 7,966.00 596.00
2012-12-31 24,248.00 2,521.00 7,857.00 598.00
2012-09-30 23,787.00 2,584.00 7,611.00 597.00

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Getinge has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Getinge has efficiently used its assets last year compared to the DE Medical Equipment industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Getinge improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Getinge's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Getinge has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Getinge's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Getinge's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Getinge is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Getinge's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Getinge's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 1.3x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Getinge Company Filings, last reported 3 weeks ago.

DB:GTN Past Debt and Equity Data
Date (Data in SEK Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 20,014.00 10,714.00 1,158.00
2019-03-31 20,219.00 10,685.00 993.00
2018-12-31 19,655.00 10,910.00 1,273.00
2018-09-30 18,905.00 10,732.00 940.00
2018-06-30 20,668.00 11,562.00 939.00
2018-03-31 20,062.00 10,946.00 1,037.00
2017-12-31 19,806.00 11,237.00 1,526.00
2017-09-30 23,755.00 16,148.00 1,521.00
2017-06-30 20,060.00 20,897.00 1,400.00
2017-03-31 20,648.00 21,728.00 2,334.00
2016-12-31 20,916.00 22,124.00 1,680.00
2016-09-30 19,251.00 21,929.00 1,812.00
2016-06-30 18,977.00 22,071.00 1,845.00
2016-03-31 19,112.00 21,730.00 2,056.00
2015-12-31 19,593.00 21,283.00 1,468.00
2015-09-30 18,855.00 21,898.00 1,544.00
2015-06-30 18,825.00 21,593.00 1,392.00
2015-03-31 18,577.00 22,277.00 2,027.00
2014-12-31 18,694.00 20,740.00 1,482.00
2014-09-30 16,787.00 19,997.00 1,064.00
2014-06-30 16,284.00 19,094.00 1,064.00
2014-03-31 15,404.00 16,205.00 1,155.00
2013-12-31 16,560.00 17,151.00 1,628.00
2013-09-30 15,314.00 16,225.00 1,237.00
2013-06-30 14,839.00 18,630.00 1,080.00
2013-03-31 15,052.00 0.00 1,075.00
2012-12-31 15,200.00 17,500.00 1,521.00
2012-09-30 14,513.00 17,298.00 1,392.00
  • Getinge's level of debt (53.5%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (117.3% vs 53.5% today).
  • Debt is well covered by operating cash flow (28.8%, greater than 20% of total debt).
  • Getinge is making a loss, therefore interest payments are not well covered by earnings.
X
Financial health checks
We assess Getinge's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Getinge has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Getinge's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0.72%
Current annual income from Getinge dividends. Estimated to be 1.58% next year.
If you bought €2,000 of Getinge shares you are expected to receive €14 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Getinge's pays a lower dividend yield than the bottom 25% of dividend payers in Germany (1.48%).
  • Getinge's dividend is below the markets top 25% of dividend payers in Germany (3.92%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:GTN Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 10 Analyst Estimates (S&P Global) See Below
Germany Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 8 Stocks 1.4%
Germany Market Average Dividend Yield Market Cap Weighted Average of 325 Stocks 3.2%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.5%
Germany Top 25% Dividend Yield 75th Percentile 3.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:GTN Future Dividends Estimate Data
Date (Data in SEK) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31 3.14 1.00
2021-12-31 2.76 7.00
2020-12-31 2.07 9.00
2019-12-31 1.66 7.00
DB:GTN Past Annualized Dividends Data
Date (Data in SEK) Dividend per share (annual) Avg. Yield (%)
2019-03-20 1.000 0.773
2018-03-23 1.500 1.631
2017-03-29 2.000 1.433
2016-02-25 2.800 1.722
2015-02-18 2.800 1.362
2014-01-28 4.150 2.270
2013-02-14 4.150 1.967
2012-03-28 3.750 1.943
2011-05-02 3.250 1.928
2010-04-21 2.750 1.790
2009-04-21 2.400 1.928

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Getinge is not paying a notable dividend for Germany, therefore no need to check if the payments are stable.
  • Getinge is not paying a notable dividend for Germany, therefore no need to check if the payments are increasing.
Current Payout to shareholders
What portion of Getinge's earnings are paid to the shareholders as a dividend.
  • No need to calculate the sustainability of Getinge's dividends as it is not paying a notable one for Germany.
Future Payout to shareholders
  • Dividends after 3 years are expected to be well covered by earnings (3.2x coverage).
X
Income/ dividend checks
We assess Getinge's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Getinge afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Getinge has a total score of 1/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Getinge's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Mattias Perjos
COMPENSATION SEK33,560,000
AGE 47
TENURE AS CEO 2.3 years
CEO Bio

Mr. Mattias Perjos has been the Chief Executive Officer and President at Getinge AB since March 27, 2017. Mr. Perjos serves as Chief Executive Officer at FlexLink Systems, Inc. Mr. Perjos has been the Director of Area Asia Pacific of Flexlink AB since 1997. He serves as Managing Director of Coesia International which includes the subsidiaries in China, Japan, South Korea, South-East Asia, India, the Americas, Russia, Africa and the Middle East. He joined Getinge from the Coesia Group, a privately owned Italian group of companies, where he holds the position as Chief Executive Officer of the IPS Division and a member of Group management since 2012. He has been a Director of Getinge AB since March 29, 2017.

CEO Compensation
  • Mattias's compensation has increased whilst company is loss making.
  • Mattias's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Getinge management team in years:

2.3
Average Tenure
52
Average Age
  • The tenure for the Getinge management team is about average.
Management Team

Mattias Perjos

TITLE
CEO, President & Director
COMPENSATION
SEK34M
AGE
47
TENURE
2.3 yrs

Lars Sandström

TITLE
Chief Financial Officer
AGE
47
TENURE
1.6 yrs

Lars Mattson

TITLE
Head of Investor Relations

Lena Hagman

TITLE
Executive Vice President of Quality & Regulatory Compliance
AGE
54
TENURE
3.5 yrs

Abraham Ronai

TITLE
General Counsel

Jeanette Carlsson

TITLE
Executive Vice President of Communications & Academy
AGE
53
TENURE
2.1 yrs

Magnus Lundbäck

TITLE
Executive Vice President of Human Resources & Sustainability
AGE
50
TENURE
2.5 yrs

Dieter Engel

TITLE
Chief Technology Officer of Surgical Workflows
TENURE
3.5 yrs

Carsten Blecker

TITLE
Chief Commercial Officer
AGE
53
TENURE
1.6 yrs

Jens Viebke

TITLE
President of Acute Care Therapies
AGE
52
Board of Directors Tenure

Average tenure and age of the Getinge board of directors in years:

5.5
Average Tenure
59
Average Age
  • The tenure for the Getinge board of directors is about average.
Board of Directors

Johan Malmquist

TITLE
Chairman
COMPENSATION
SEK684K
AGE
58
TENURE
0.3 yrs

Mattias Perjos

TITLE
CEO, President & Director
COMPENSATION
SEK34M
AGE
47
TENURE
2.3 yrs

Johan Stern

TITLE
Vice Chairman
COMPENSATION
SEK684K
AGE
68

Carl Bennet

TITLE
Director
COMPENSATION
SEK1M
AGE
68
TENURE
30.5 yrs

Johan Bygge

TITLE
Director
COMPENSATION
SEK852K
AGE
63
TENURE
12.3 yrs

Cecilia Wennborg

TITLE
Director
COMPENSATION
SEK722K
AGE
56
TENURE
9.3 yrs

Peter Jörmalm

TITLE
Employee Representative Director
AGE
60
TENURE
1.5 yrs

Rickard Karlsson

TITLE
Employee Representative Director
AGE
49
TENURE
6.5 yrs

Malin Persson

TITLE
Director
COMPENSATION
SEK684K
AGE
51
TENURE
5.5 yrs

Barbro Fridén

TITLE
Director
COMPENSATION
SEK684K
AGE
63
TENURE
2.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
09. Nov 18 Buy Malin Persson Individual 09. Nov 18 09. Nov 18 2,000 €8.34 €16,674
01. Nov 18 Buy Lars Sandström Individual 01. Nov 18 01. Nov 18 3,000 €7.87 €23,601
31. Oct 18 Buy Johan Bygge Individual 29. Oct 18 29. Oct 18 3,000 €8.44 €25,329
19. Oct 18 Buy Johan Malmquist Individual 19. Oct 18 19. Oct 18 26,509 €7.91 €209,693
X
Management checks
We assess Getinge's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Getinge has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Getinge AB provides products and solutions for operating rooms, intensive-care units, sterilization departments, and life science companies and institutions. The company operates through Acute Care Therapies, Surgical Workflows, and Life Science segments. It offers practice-oriented monitoring systems and disposables; anesthesia, beating heart surgery, and ceiling devices; washer-disinfectors, consumables, and IT-solutions; connected solutions; consumables products; drain products; endoscope reprocessing; endoscopic vessel harvesting systems; extracorporeal life support or extracorporeal membrane oxygenation products; inspection and packaging services; intra-aortic balloon counter pulsation therapies; critical care ventilators; modular room systems; operating lights; operating tables and accessories; operating room (OR) furniture; OR integration systems; patient flow management solutions; patient transport solutions; sealing equipment; sterile supply management and traceability solutions; sterilizers; surgical assist systems; surgical perfusion components; loading and distribution trolleys; trays and baskets; and after sales consulting services. The company also provides automated bedding handling equipment, closure processing systems, washers, and isolation and sterile transfer products; professional financial advisory services to hospitals and medical facilities; and education and training services. It offers its products through a network of proprietary sales companies, as well as through agents and distributors in Europe, the Middle East, Africa, the Americas, Asia, and Pacific. The company has a strategic partnership with Verb Surgical Inc. to develop digital surgery solutions. Getinge AB was founded in 1904 and is headquartered in Gothenburg, Sweden.

Details
Name: Getinge AB
GTN
Exchange: DB
Founded: 1904
SEK3,585,393,399
272,369,573
Website: http://www.getinge.com
Address: Getinge AB
Lindholmspiren 7,
Gothenburg,
Västra Götaland County, 417 56,
Sweden
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OM GETI B Class B Shares OMX Nordic Exchange Stockholm SE SEK 21. May 1993
OTCPK GNGB.F Class B Shares Pink Sheets LLC US USD 21. May 1993
DB GTN Class B Shares Deutsche Boerse AG DE EUR 21. May 1993
LSE 0GZV Class B Shares London Stock Exchange GB SEK 21. May 1993
BATS-CHIXE GETIBS Class B Shares BATS 'Chi-X Europe' GB SEK 21. May 1993
OTCPK GNGB.Y UNSPONSORD ADR Pink Sheets LLC US USD 13. Oct 2008
Number of employees
Current staff
Staff numbers
10,409
Getinge employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/07/22 20:51
End of day share price update: 2019/07/22 00:00
Last estimates confirmation: 2019/07/22
Last earnings filing: 2019/07/17
Last earnings reported: 2019/06/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.